HAO
Haoxi Health·NASDAQ
--
--(--)
--
--(--)
0.87 / 10
Underperform
The equity presents poor fundamental picture (0.9/10). Strengths include Inventory turnover days, balanced by issues in Operating cycle and Net assets per share (growth rate compared to beginning of year %). This merits challenging consideration.
Analysis Checks(1/3)
Net assets per share (growth rate compared to beginning of year %)
Value1615.81
Score0/3
Weight72.43%
1M Return-2.62%
Value1615.81
Score0/3
Weight72.43%
1M Return-2.62%
Inventory turnover days
Value300.47
Score2/3
Weight2.72%
1M Return-0.09%
Value300.47
Score2/3
Weight2.72%
1M Return-0.09%
Operating cycle
Value3.77
Score1/3
Weight24.85%
1M Return-0.91%
Value3.77
Score1/3
Weight24.85%
1M Return-0.91%
Net assets per share (growth rate compared to beginning of year %)
Value1615.81
Score0/3
Weight72.43%
1M Return-2.62%
Value1615.81
Score0/3
Weight72.43%
1M Return-2.62%
Operating cycle
Value3.77
Score1/3
Weight24.85%
1M Return-0.91%
Value3.77
Score1/3
Weight24.85%
1M Return-0.91%
Inventory turnover days
Value300.47
Score2/3
Weight2.72%
1M Return-0.09%
Value300.47
Score2/3
Weight2.72%
1M Return-0.09%
Is HAO undervalued or overvalued?
- HAO scores 0.87/10 on fundamentals and holds a Premium valuation at present. Backed by its 27.06% ROE, 11.82% net margin, 16.87 P/E ratio, 3.76 P/B ratio, and 56.60% earnings growth, these metrics solidify its Underperform investment rating.
